Showing results 1 to 20 of 40
next >
| Rights | Preview | Issue Date | Title | Author(s) | Type |
| closedAccess |  | 2005 | Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin | Yuste, Laura; Montero, Juan Carlos  ; Esparís-Ogando, Azucena ; Pandiella, Atanasio | artículo |
| closedAccess |  | 2012 | Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer | Montero, Juan Carlos ; Esparís-Ogando, Azucena ; Re-Louhau, M. F. ; Seoane, Samuel ; Abad, María del Mar; Calero, R.; Ocaña, Alberto; Pandiella, Atanasio | artículo |
| openAccess |  | 30-Aug-2019 | Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer | Noblejas-López, María del Mar; Nieto-Jimenez, Cristina; Burgos, Miguel; Gómez-Juárez, Mónica; Montero, Juan Carlos ; Esparís-Ogando, Azucena ; Pandiella, Atanasio ; Galán-Moya, Eva M.; Ocaña, Alberto | artículo |
| openAccess |  | 2015 | Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer | Cuenca-López, María D.; Serrano-Heras, Gemma ; Montero, Juan Carlos ; Morales, Jorge C.; Pandiella, Atanasio ; Ocaña, Alberto | artículo |
| openAccess |  | 2015 | Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2 | Pandiella, Atanasio ; Morís, Francisco; Ocaña, Alberto; Núñez, Luz-Elena; Montero, Juan Carlos | artículo |
| closedAccess |  | 2008 | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo | Mitsiades, C. S.; Ocio, Enrique M. ; Pandiella, Atanasio ; Maiso, Patricia; Gajate, Consuelo; Garayoa, Mercedes ; Vilanova, David; Montero, Juan Carlos ; Mollinedo, Faustino ; San Miguel, Jesús F. | artículo |
| closedAccess |  | 2016 | Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node | Seoane, Samuel ; Montero, Juan Carlos ; Ocaña, Alberto; Pandiella, Atanasio | artículo |
| closedAccess |  | 1999 | Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms | Díaz-Rodríguez, Elena ; Cabrera, Noemí ; Esparís-Ogando, Azucena ; Montero, Juan Carlos ; Pandiella, Atanasio | artículo |
| openAccess |  | 2017 | CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia | Guerra, Borja; Martín-Rodríguez, Patricia; Díaz-Chico, Juan Carlos; McNaughton-Smith, Grant; Jiménez-Alonso, Sandra; Hueso-Falcón, Idaira; Montero, Juan Carlos ; Blanco, Rosa ; León, Javier ; Rodríguez-González, Germán; Estévez-Braun, Ana; Pandiella, Atanasio ; Díaz-Chico, Bonifacio Nicolás; Fernández-Pérez, Leandro | artículo |
| closedAccess |  | 2000 | Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-α-converting enzyme | Montero, Juan Carlos ; Yuste, Laura; Díaz-Rodríguez, Elena ; Esparís-Ogando, Azucena ; Pandiella, Atanasio | artículo |
| openAccess |  | 22-Sep-2010 | Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells | Seoane, Samuel ; Montero, Juan Carlos ; Ocaña, Alberto; Pandiella, Atanasio | artículo |
| closedAccess |  | 2010 | Enhancement of antiproliferative activity by molecular simplification of catalpol | García, Celina; Ríos-Luci, Carla; Montero, Juan Carlos ; Pandiella, Atanasio | artículo |
| closedAccess |  | 2007 | Erk5 is activated and acts as a survival factor in mitosis | Gírio, Ana; Montero, Juan Carlos ; Pandiella, Atanasio | artículo |
| closedAccess |  | Jan-2002 | Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2 | Esparís-Ogando, Azucena ; Díaz-Rodríguez, Elena ; Montero, Juan Carlos ; Yuste, Laura; Crespo, Piero ; Pandiella, Atanasio | artículo |
| openAccess |  | 15-May-2009 | Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target | Montero, Juan Carlos ; Ocaña, Alberto; Abad, María del Mar; Ortiz-Ruiz, María Jesús ; Pandiella, Atanasio ; Esparís-Ogando, Azucena | artículo |
| openAccess |  | 2015 | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling | Montero, Juan Carlos ; García-Alonso, Sara; Ocaña, Alberto; Pandiella, Atanasio | artículo |
| closedAccess |  | 2016 | In silico analysis guides selection of BET Inhibitors for triple-negative breast cancer treatment | Pérez-Peña, Javier; Serrano-Heras, Gemma ; Montero, Juan Carlos ; Corrales-Sánchez, Verónica; Pandiella, Atanasio ; Ocaña, Alberto | artículo |
| closedAccess |  | 2015 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone | Ocio, Enrique M. ; Fernández-Lázaro, Diego; San-Segundo, Laura; López-Corral, L.; Corchete, Luis A.; Gutiérrez, Norma Carmen; Garayoa, Mercedes ; Paíno, Teresa ; García-Gómez, Antonio; Delgado, Manuel; Montero, Juan Carlos ; Díaz-Rodríguez, Elena ; Mateos, Maria Victoria; Pandiella, Atanasio ; San Miguel, Jesús F. | artículo |
| closedAccess |  | 2011 | Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors | Montero, Juan Carlos ; Seoane, Samuel ; Ocaña, Alberto; Pandiella, Atanasio | artículo |
| closedAccess |  | 2010 | Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors | León, Leticia G.; Tejedor, David ; Montero, Juan Carlos ; Pandiella, Atanasio ; García-Tellado, Fernando ; Padrón, José M. | artículo |
